Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

* Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (AZA/6-MP); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC * Patients who are able to complete patients questionnaires (e.g., WPAI:UC and sIBDQ questionnaire) * Patients must fulfill national and international guidelines for the use of biologic therapies in UC (Chest X-ray and Interferon-Gamma-Release Assay (IGRA) or tuberculin purified protein derivative (PPD)-skin test negative for tuberculosis). * Patients who have been prescribed adalimumab in line with the European SmPC (Summary of Product Characteristics)

* Previous therapy with TNF-alpha (Tumor necrosis factor alpha) blocker * No signed written authorization to use data * Contraindication to adalimumab therapy according to the SmPC * Patients with a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC or planned bowel surgery. * Patients received intravenous (IV) corticosteroids within 14 days of Screening or during the Screening period. * Pregnant patients